Back to Report Store Home

Global Dermatology Drugs Market to 2024 – IL Signaling Inhibitors to Overtake TNF-a Inhibitors as Leading Commercial Drug Class with Dupixent and Cosentyx among Key Performers

  • Published: Dec-2018
  • Report Code: GBIHC486MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Therapy Area Introduction

2.2 Symptoms

2.3 Diagnosis, Scales and Grading

2.3.1 Atopic Dermatitis

2.3.2 Acne Vulgaris

2.3.3 Psoriasis

2.4 Etiology

2.5 Pathophysiology

2.5.1 Atopic Dermatitis

2.5.2 Acne Vulgaris

2.5.3 Psoriasis

2.6 Epidemiology

2.6.1 Atopic Dermatitis

2.6.2 Acne Vulgaris

2.6.3 Psoriasis

2.7 Comorbidities and Complications

2.8 Treatment

2.8.1 Topical Corticosteroids

2.8.2 Calcineurin Inhibitors

2.8.3 Retinoids

2.8.4 Systemic Immunosuppressive Agents

2.8.5 Biologics

2.8.6 Antihistamines

2.8.7 Hormonal Therapy

2.8.8 Moisturizers

3 Key Marketed Products

3.1 Overview

3.2 Humira (adalimumab) - AbbVie

3.3 Enbrel (etanercept) - Amgen

3.4 Remicade (infliximab) – Johnson & Johnson

3.5 Stelara (ustekinumab) – Johnson & Johnson

3.6 Cosentyx (secukinumab) - Novartis

3.7 Taltz (ixekizumab) – Eli Lilly

3.8 Dupixent (dupilumab) - Sanofi

3.9 Eucrisa (crisaborole) - Pfizer

3.10 Neoral (cyclosporine) – Novartis

3.11 Protopic (Tacrolimus) – Leo Pharma

3.12 Elidel (pimecrolimus) – Bausch Health

3.13 Differin (adapalene) – Galderma

3.14 Elocon (mometasone furoate) – Merck & Co.

3.15 Metolate (methotrexate)

3.16 Clobex (clobetasol propionate) – Galderma

3.17 Aczone (dapsone) – Almirall

3.18 Retin-A (tretinoin) – Bausch Health

3.19 Episalvan (birch bark extract) – Amryt Pharma

4 Pipeline Landscape Assessment

4.1 Overview

4.2 Pipeline Development Landscape

4.3 Molecular Targets in the Pipeline

4.4 Clinical Trials

4.4.1 Clinical Trial Failure Rates

4.4.2 Clinical Trial Duration

4.4.3 Clinical Trial Size

4.4.4 Cumulative Clinical Program Size

4.5 Assessment of Key Late-Stage Pipeline Products

4.5.1 Risankizumab – AbbVie

4.5.2 MOR106 – MorphoSys/Galapagos/Novartis

4.5.3 ANB-019 – AnaptysBio

4.5.4 Lebrikizumab – Dermira

4.5.5 FMX-101 (minocycline) – Foamix

5 Multi-scenario Market Forecast to 2024

5.1 Overall Market Size

5.2 Generic Penetration

5.3 Revenue Forecast by Molecular Target Class

5.3.1 TNF-a inhibitors

5.3.2 IL-17 inhibitors

5.3.3 IL-23 inhibitors

5.3.4 Other IL inhibitors (ILs 1, 4, 12, 13, 33 and 36 and receptors)

5.3.5 PDE4 inhibitors

5.3.6 Glucocorticoids

5.3.7 JAK inhibitors

6 Company Analysis and Positioning

6.1 Revenue and Market Share Analysis by Company

6.1.1 AbbVie – Company to maintain market leadership despite declining market share

6.1.2 Novartis – Success of Cosentyx to increase company’s market share

6.1.3 Johnson & Johnson – Stelara and Tremfya to offset revenue losses from Remicade

6.1.4 Sanofi – Company to become one of the leading players due to Dupixent’s success

6.1.5 Pfizer – Approval of Eucrisa to drive growth in the dermatology therapy area

6.1.6 Eli Lilly – New products Taltz and Olumiant to drive market growth

6.2 Company Landscape

6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations

7.1 Licensing Deals

7.1.1 Deals by Region, Deal Value and Year

7.1.2 Deals by Indication and Deal Value

7.1.3 Deals by Stage of Development and Deal Value

7.1.4 Deals by Molecule Type, Molecular Target and Deal Value

7.1.5 Figures of Licensing Deals with Disclosed Values

7.2 Co-development Deals

7.2.1 Deals by Region, Deal Value and Year

7.2.2 Deals by Indication and Deal Value

7.2.3 Deals by Stage of Development and Deal Value

7.2.4 Deals by Molecule Type, Molecular Target and Deal Value

7.2.5 Figures of Co-development Deals with Disclosed Values

8 Appendix

8.1 References

8.2 Figures of All Clinical Stage Pipeline Products

8.3 Abbreviations

8.4 Disease List

8.5 Methodology

8.5.1 Coverage

8.5.2 Secondary Research

8.5.3 Market Size and Revenue Forecasts

8.5.4 Pipeline Analysis

8.5.5 Competitive Landscape

8.6 Contact Us

8.7 Disclaimer

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards